Humoral hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting neuroendocrine tumors: Report of six cases

Anna Milanesi, Run Yu, Edward M. Wolin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We report the clinical characteristics and management of six patients with metastatic gastroenteropancreatic neuroendocrine tumor (NET) presenting with severe hypercalcemia due to elevation of parathyroid hormone-related protein (PTHrP). All patients had histological confirmation of NET, five well-differentiated and one poorly differentiated. In 5 patients, hypercalcemia developed after years after the initial diagnosis of NET. One patient presented with concomitant elevation of PTHrP and intact parathyroid hormone (PTH) in the setting of multiple endocrine neoplasia 1 (MEN1). In all the other cases, PTH levels were low or undetectable. Management of malignant hypercalcemia due to PTHrP-producing NET is challenging, and optimal therapy depends on the extent of metastatic disease and the grade of malignancy. Aggressive tumor cytoreduction in addition to the systemic treatment modalities is frequently used to control disease progression and endocrine symptoms. To our knowledge, this is the largest series to date of hypercalcemia mediated by PTHrP-secreting NET.

Original languageEnglish (US)
Pages (from-to)324-326
Number of pages3
JournalPancreatology
Volume13
Issue number3
DOIs
StatePublished - May 2013
Externally publishedYes

Fingerprint

Parathyroid Hormone-Related Protein
Neuroendocrine Tumors
Hypercalcemia
Parathyroid Hormone
Multiple Endocrine Neoplasia
Disease Progression
Neoplasms
Humoral Hypercalcemia Of Malignancy
Therapeutics

Keywords

  • Hypercalcemia
  • Neuroendocrine tumor
  • PTHrP

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology

Cite this

Humoral hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting neuroendocrine tumors : Report of six cases. / Milanesi, Anna; Yu, Run; Wolin, Edward M.

In: Pancreatology, Vol. 13, No. 3, 05.2013, p. 324-326.

Research output: Contribution to journalArticle

@article{082a5f0e5e844cbe95b924b721074121,
title = "Humoral hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting neuroendocrine tumors: Report of six cases",
abstract = "We report the clinical characteristics and management of six patients with metastatic gastroenteropancreatic neuroendocrine tumor (NET) presenting with severe hypercalcemia due to elevation of parathyroid hormone-related protein (PTHrP). All patients had histological confirmation of NET, five well-differentiated and one poorly differentiated. In 5 patients, hypercalcemia developed after years after the initial diagnosis of NET. One patient presented with concomitant elevation of PTHrP and intact parathyroid hormone (PTH) in the setting of multiple endocrine neoplasia 1 (MEN1). In all the other cases, PTH levels were low or undetectable. Management of malignant hypercalcemia due to PTHrP-producing NET is challenging, and optimal therapy depends on the extent of metastatic disease and the grade of malignancy. Aggressive tumor cytoreduction in addition to the systemic treatment modalities is frequently used to control disease progression and endocrine symptoms. To our knowledge, this is the largest series to date of hypercalcemia mediated by PTHrP-secreting NET.",
keywords = "Hypercalcemia, Neuroendocrine tumor, PTHrP",
author = "Anna Milanesi and Run Yu and Wolin, {Edward M.}",
year = "2013",
month = "5",
doi = "10.1016/j.pan.2013.02.007",
language = "English (US)",
volume = "13",
pages = "324--326",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Humoral hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting neuroendocrine tumors

T2 - Report of six cases

AU - Milanesi, Anna

AU - Yu, Run

AU - Wolin, Edward M.

PY - 2013/5

Y1 - 2013/5

N2 - We report the clinical characteristics and management of six patients with metastatic gastroenteropancreatic neuroendocrine tumor (NET) presenting with severe hypercalcemia due to elevation of parathyroid hormone-related protein (PTHrP). All patients had histological confirmation of NET, five well-differentiated and one poorly differentiated. In 5 patients, hypercalcemia developed after years after the initial diagnosis of NET. One patient presented with concomitant elevation of PTHrP and intact parathyroid hormone (PTH) in the setting of multiple endocrine neoplasia 1 (MEN1). In all the other cases, PTH levels were low or undetectable. Management of malignant hypercalcemia due to PTHrP-producing NET is challenging, and optimal therapy depends on the extent of metastatic disease and the grade of malignancy. Aggressive tumor cytoreduction in addition to the systemic treatment modalities is frequently used to control disease progression and endocrine symptoms. To our knowledge, this is the largest series to date of hypercalcemia mediated by PTHrP-secreting NET.

AB - We report the clinical characteristics and management of six patients with metastatic gastroenteropancreatic neuroendocrine tumor (NET) presenting with severe hypercalcemia due to elevation of parathyroid hormone-related protein (PTHrP). All patients had histological confirmation of NET, five well-differentiated and one poorly differentiated. In 5 patients, hypercalcemia developed after years after the initial diagnosis of NET. One patient presented with concomitant elevation of PTHrP and intact parathyroid hormone (PTH) in the setting of multiple endocrine neoplasia 1 (MEN1). In all the other cases, PTH levels were low or undetectable. Management of malignant hypercalcemia due to PTHrP-producing NET is challenging, and optimal therapy depends on the extent of metastatic disease and the grade of malignancy. Aggressive tumor cytoreduction in addition to the systemic treatment modalities is frequently used to control disease progression and endocrine symptoms. To our knowledge, this is the largest series to date of hypercalcemia mediated by PTHrP-secreting NET.

KW - Hypercalcemia

KW - Neuroendocrine tumor

KW - PTHrP

UR - http://www.scopus.com/inward/record.url?scp=84884674758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884674758&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2013.02.007

DO - 10.1016/j.pan.2013.02.007

M3 - Article

C2 - 23719609

AN - SCOPUS:84884674758

VL - 13

SP - 324

EP - 326

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

IS - 3

ER -